528 related articles for article (PubMed ID: 20721603)
21. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy.
Zhu G; Mei L; Vishwasrao HD; Jacobson O; Wang Z; Liu Y; Yung BC; Fu X; Jin A; Niu G; Wang Q; Zhang F; Shroff H; Chen X
Nat Commun; 2017 Nov; 8(1):1482. PubMed ID: 29133898
[TBL] [Abstract][Full Text] [Related]
22. Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective.
Wu QJ; Lv WL
IET Nanobiotechnol; 2024; 2024():5593879. PubMed ID: 38863969
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.
Chesson CB; Zloza A
Nanomedicine (Lond); 2017 Dec; 12(23):2693-2706. PubMed ID: 29098928
[TBL] [Abstract][Full Text] [Related]
24. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
25. Cancer Immunotherapy: From local to global.
Mulder WJM; Gnjatic S
Nat Nanotechnol; 2017 Sep; 12(9):840-841. PubMed ID: 28875982
[No Abstract] [Full Text] [Related]
26. Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
Wakabayashi R; Sakuragi M; Kozaka S; Tahara Y; Kamiya N; Goto M
Mol Pharm; 2018 Mar; 15(3):955-961. PubMed ID: 29397746
[TBL] [Abstract][Full Text] [Related]
27. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
[TBL] [Abstract][Full Text] [Related]
28. Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C; Rammensee HG
Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
[TBL] [Abstract][Full Text] [Related]
29. Synthetic Particles for Cancer Vaccines: Connecting the Inherent Supply Chain.
Xia Y; Song T; Hu Y; Ma G
Acc Chem Res; 2020 Oct; 53(10):2068-2080. PubMed ID: 32945648
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells.
Yoshikawa T; Okada N; Oda A; Matsuo K; Matsuo K; Kayamuro H; Ishii Y; Yoshinaga T; Akagi T; Akashi M; Nakagawa S
Vaccine; 2008 Mar; 26(10):1303-13. PubMed ID: 18255205
[TBL] [Abstract][Full Text] [Related]
31. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.
Lynn GM; Laga R; Jewell CM
Cancer Lett; 2019 Sep; 459():192-203. PubMed ID: 31185250
[TBL] [Abstract][Full Text] [Related]
32. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
Cadete A; Alonso MJ
Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
[TBL] [Abstract][Full Text] [Related]
33. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
34. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
35. Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.
Fang RH; Kroll AV; Zhang L
Small; 2015 Nov; 11(41):5483-96. PubMed ID: 26331993
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy.
Kuai R; Sun X; Yuan W; Xu Y; Schwendeman A; Moon JJ
Bioconjug Chem; 2018 Mar; 29(3):771-775. PubMed ID: 29485848
[TBL] [Abstract][Full Text] [Related]
37. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticle mediated cancer immunotherapy.
Gupta J; Safdari HA; Hoque M
Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
[TBL] [Abstract][Full Text] [Related]
39. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
40. IL-13 receptor-directed cancer vaccines and immunotherapy.
Nakashima H; Husain SR; Puri RK
Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
